
GLUE Stock Forecast & Price Target
GLUE Analyst Ratings
Bulls say
Monte Rosa Therapeutics is supported by a differentiated QuEEN platform that has already generated clinical proof-of-concept across three distinct molecular glue degraders, reducing target-risk and strengthening confidence in repeatable discovery. MRT-8102 showed deep human pharmacology, including an 85% median hsCRP reduction and no AE-related discontinuations at 5mg, while MRT-2359 produced PSA50 responses in all five retrospectively identified AR-mutant mCRPC patients with radiographic shrinkage, and MRT-6160 is advancing under a Novartis-funded Phase 2 with a $50M milestone and retained economics. The company also appears financially well-positioned, with about $626 million in cash at June 30, 2026 and guidance to fund operations into 2029, allowing multiple near-term catalysts to test the platform’s clinical and commercial value.
Bears say
Monte Rosa Therapeutics is constrained by an early-stage profile with no product revenue, leaving value heavily dependent on collaboration funding, disciplined spending, and successful clinical execution across MRT-8102, MRT-2359, and MRT-6160. The investment case is weakened by clear safety and dosing uncertainty in MRT-8102, where all eight AE-related discontinuations occurred at 20–40mg and four weeks at 5mg in 27 participants does not establish chronic tolerability, while the program also faces a low cardiovascular probability of approval at 15% and a redesign that pushes GFORCE-2 initiation to 1H27. Competitive and translational risk is elevated because only MRT-2359 has any patient signal from a post hoc five-patient subset, Novartis controls key GLUE economics, and the broader platform still must prove repeatable target discovery, selective degradation, and durable clinical benefit.
This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
GLUE Analyst Forecast & Price Prediction
Start investing in GLUE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Monte Rosa Therapeutics (GLUE) Forecast
GLUE Analyst Forecast & Price Prediction
Start investing in GLUE
Order type
Buy in
Order amount
Est. shares
0 shares